International Programs

As a global company, Pfizer is committed to contributing significantly to humanitarian and health problems around the world, through the many community and philanthropic programs of other Pfizer country organizations and through a number of important international partnerships.

HIV/AIDS Diflucan Partnership Program

Pfizer has developed an innovative partnership program to make its antifungal medication Diflucan available free of charge to HIV/AIDS patients in developing countries who suffer from common and serious fungal infections. Since 2000, 185 institutions in South Africa have begun to distribute Diflucan through this program. Successful implementation in South Africa has resulted in the program being expanded to other African countries, with plans to eventually extend the platform to some 50 of the world's least-developed nations where HIV/AIDS is rampant. Pfizer's support has no dollar or time limit.

African HIV/AIDS Medical Facility

One of the major challenges in addressing the HIV/ AIDS crisis in Africa is lack of a proper healthcare infrastructure. In partnership with the Academic Alliance for AIDS Care and Prevention and other non-governmental organizations, Pfizer is helping remedy this by financing the creation of a major HIV/ AIDS hospital and training centre in Kampala, Uganda. The new centre will provide much-needed laboratory and treatment facilities, as well as a place for physicians from across Africa to receive vital training to fight this deadly epidemic.

International Trachoma Initiative

Trachoma is the leading cause of preventable blindness in the world, an easily transmissible disease that threatens 10 percent of the world's population. However, it can easily be prevented and treated with antibiotics. Pfizer's antibiotic Zithromax is ideal for this because it can be administered in just one annual dose. In 1998, Pfizer partnered with the Edna McConnell Foundation to establish the International Trachoma Initiative. In 2001, Pfizer donated 4 million doses of Zithromax to the effort to eliminate trachoma in developing nations. In Morocco, the prevalence of the disease has already been reduced by 75% and is expected to be eliminated entirely by 2005, testimony to the success of this program.

To learn more about Pfizer's international aid programs, as well as initiatives in the U.S., visit www.pfizer.com